CREATION.co’s Post

CREATION.co's HCP trackers are free resources where you can catch a glimpse into what's getting HCPs talking online, in various therapy areas. We've just launched a new one, focused on US HCP conversations about #COPD. Let me know what you think! And if you're in respiratory disease or COPD, follow CREATION.co to be the first to know. Well done to my CREATION.co colleagues Eden Daniel and Jerin Thomas for this first edition!

For anyone treating patients with COPD, The 2024 GOLD International COPD Conference is a must-attend event. Hear directly from researchers about recent latest studies and bring insights back to your patients!    Day One: Focus on Treatments Dive into a comprehensive slate of sessions exploring new and emerging therapies for COPD. You’ll gain insights into the latest advances, new interventions, and updates on current pharmacological treatments. Day Two: COPD in Depth Immerse yourself in six plenary sessions covering critical topics: Spirometry Novel drugs in COPD Updates to the 2025 GOLD Report COPD phenotypes and their multimorbidity patterns The role of telemedicine and digital tools in COPD management Upcoming novel treatments Seats are filling up fast—secure yours before the conference sells out. #GOLDCOPD2024 https://bit.ly/4bNNAUV

For anyone treating patients with COPD, The 2024 GOLD International COPD Conference is a must-attend event. Hear directly from researchers about their latest studies, and bring insights back to your patients. Day One: Focus on Treatments Dive into a comprehensive slate of sessions exploring new and emerging therapies for COPD. You’ll gain insights into the latest advances, new interventions, and updates on current pharmacological treatments. Day Two: COPD in Depth Immerse yourself in six plenary sessions covering critical topics: Spirometry Novel drugs in COPD Updates to the 2025 GOLD Report COPD phenotypes and their multimorbidity patterns The roleof telemedicine and digital tools in COPD management Upcoming novel treatments Seats are filling up fast—secure yours before the conference sells out. #GOLDCOPD2024 https://bit.ly/3MDoiO3

I recently shared with you that COPD is the third leading cause of death worldwide.   While that’s of course still true, I’m so encouraged to see the clinical community coming together to make progress and address this startling statistic. Leading experts Prof. Frederik Trinkmann and Prof. Chris Gale recently authored a piece in BMJ advocating for proactive and timely interventions to address cardiopulmonary risk and prevent exacerbations.   The article highlights how COPD patients face higher risks of both lung and heart events, and that this elevated cardiopulmonary risk can persist for up to a year following an exacerbation.   It’s clear that more proactive and preventative COPD care is urgently needed. At AstraZeneca, we’re advancing the science to create a deeper understanding of cardiopulmonary risk in COPD, working to transform outcomes and reduce the risk of premature death for the millions worldwide living with COPD. Learn more about how care can evolve: https://bit.ly/4ceF2GO #WhatScienceCanDo

It is estimated that COPD affects 391 million people worldwide (using GOLD definition of COPD)¹—that’s equivalent to the population of 47 New York Cities or 44 Londons, 10 Tokyos, or 28 Rio De Janeiros. Yet despite its massive impact, COPD often continues to be under prioritised, underfunded, and undertreated across healthcare systems globally. This #WorldCOPDDay, we are urging healthcare providers and policymakers to take decisive action by implementing standardised quality measures for COPD diagnosis and management. Consistent care is a core element in improving patient outcomes and ensuring that everyone, regardless of location, age, gender, or economic background, has access to the right care plan and support. At AstraZeneca Ireland, we are proud to Speak Up for COPD by supporting COPD Support Ireland and its plans to highlight the importance of World COPD Day. These include a ‘COPD & Me’ roadshow offering free spirometry tests across five Irish cities. In Ireland it is estimated that 380,000 people are living with COPD yet only 110,000 are diagnosed². Join us in the movement to empower patients, advocate for change, and act to improve care. Lend your voice and #SpeakUpforCOPD by visiting speakupforcopd.com to learn how you can make a difference in advancing the future of COPD care. References: ¹Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. (2022) Vol 10(5); 447-458 - https://lnkd.in/ej77M9Td ²National Healthcare Quality Reporting System Report 2021/2022 - page 89 https://lnkd.in/e-vm-GPv   Date of Preparation: November 2024 Veeva ID: IE-7120

🩺 Enhancing COPD Management in Primary Care with myCOPD 🩺 Primary care physicians, play a crucial role in the management of Chronic Obstructive Pulmonary Disease (COPD). With the rise of digital health solutions like my mhealth Inc (US)'s myCOPD, we now have powerful tools at our disposal to improve patient outcomes and engagement. 🌟 Benefits of Integrating myCOPD in Your Practice: Patient-Centered Care: myCOPD empowers patients to take an active role in their health by providing personalized action plans, medication reminders, and symptom tracking. Real-Time Monitoring: Stay informed about your patients’ symptoms and medication adherence. The app allows for better communication and timely interventions. Educational Resources: Equip your patients with knowledge about COPD management through the app’s comprehensive educational materials, enhancing their understanding of the condition. Data-Driven Insights: Leverage the analytics from myCOPD to identify trends in your patient population, helping to refine your approach and tailor interventions. Improved Outcomes: By utilizing myCOPD, we can help reduce exacerbations, hospitalizations, and overall healthcare costs, leading to better quality of life for our patients. 💬 Let’s Collaborate: How can we integrate digital tools like myCOPD in your practice? Together, we can enhance the management of COPD and empower our patients on their journey to better lung health! 💙 #COPD #PrimaryCare #myCOPD #PatientEngagement #HealthcareInnovation #LungHealth #digitalhealth

Over 11.7 million people in the U.S. have been diagnosed with chronic obstructive pulmonary disease (COPD). Education and support are essential to living well with COPD and @AstraZeneca is teaming up with the @American Lung Association (ALA) on the “Learning to Live with COPD” campaign to improve life quality for those managing the disease. This initiative provides education on treatment options and introduces a COPD-focused health navigator via ALA’s Lung HelpLine. A free webinar on November 20 will feature a COPD expert and a patient, fostering open dialogue between patients and healthcare providers. The campaign prioritizes women, low-income, and rural communities—groups disproportionately affected by COPD and facing healthcare access challenges. AstraZeneca’s COPD drug Breztri Aerosphere is climbing in sales, and with ongoing studies exploring new treatment possibilities, the focus on lung health continues. Read more here: https://lnkd.in/eqcyVDw3 Find the clinical evidence for Breztri and other drugs treatment of COPD @DRUGDOCS: https://lnkd.in/eHwsGUSF #COPDAwareness #LungHealth #HealthEquity

Nearly 50% of Australians with COPD are living undiagnosed and unsupported! Australia needs urgent improvements in COPD diagnosis and support. Lung Foundation Australia is dedicated to helping the healthcare community better understand COPD and support people living with it. Download the COPD-X Handbook for an easy to digest summary of the COPD clinical practice guidelines, with tips and advice for each key recommendation:

An invaluable resource

We asked for better care. WE WERE HEARD! 💜🩵💙 The COPD Foundation along with NTM Info & Research has launched the Bronchiectasis and NTM Care Center Network (CCN), a major initiative aimed at improving care for individuals with bronchiectasis and nontuberculous mycobacterial (NTM) lung disease. This network will be established across 150 US medical centers over three years. The CCN aims to accelerate diagnosis, provide high-quality care, educate healthcare teams, support research and clinical trials, and enhance patient education and engagement. According to Christina Hunt, BS, RRT, Senior Director of Bronchiectasis and NTM Education and Care Delivery: “The Bronchiectasis and NTM Care Center Network (CCN) has completed its first application review period and is pleased to report that 33 sites have been invited to join the CCN. The selection process was highly competitive! An official announcement with the list of designated centers will be published in December 2024. The Care Center Network is looking forward to its next Request for Applications period anticipated for February 2025. They hope to receive applications from additional sites from around the country and centers that wish to reapply. We are so thrilled that the CCN is becoming a reality!” It is my hope that this model will be used worldwide. Stay the course with self-care. Help is on the way‼️💪🏽🩵💪🏽💙💪🏽💜💪🏽 COPD Foundation NTMir Bronchiectasis Info and Research #Bronchiectasis #NTMLungDisease #COPDFoundation #NTMInfo #CareCenterNetwork #BronchiectasisCare #NTMCare #LungHealth #RespiratoryCare #PatientEducation #HealthcareInnovation #LungDiseaseAwareness #ChronicIllnessCare #MedicalResearch #ClinicalTrials #HealthcareCollaboration #ImprovingCare #RespiratorySupport #MedicalCenters #PatientEngagement #BetterBreathing #NTMAwareness #BronchiectasisAwareness #HealthcareNetwork #LungDiseaseSupport